Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 2/20 | 0.35 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454822 | 0.85 | ESR2 (0.40) | MEN1KMT2AADH5FADS1 | |
| SCHEMBL4458122 | 0.84 | CALML3 (0.42) | GRM2MEN1TSHRKMT2AFADS1 | |
| SCHEMBL4445382 | 0.83 | DHODH (0.46) | GRM2MEN1KMT2ACYP2A6 | |
| SCHEMBL4469782 | 0.83 | ROCK2 (0.37) | GRM2ADH5FADS1 | |
| SCHEMBL4474713 | 0.81 | PDE3B (0.39) | ADH5 | |
| SCHEMBL4460627 | 0.81 | ALDH1A1 (0.43) | GRM2TSHR | |
| SCHEMBL4445293 | 0.80 | ALDH1A1 (0.42) | MEN1GAAKMT2A | |
| SCHEMBL4472187 | 0.79 | GRM2 (0.36) | GRM2FADS1 | |
| SCHEMBL4444393 | 0.75 | FADS1 (0.39) | GRM2FADS1 | |
| SCHEMBL4455582 | 0.74 | TNKS (0.39) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885CSNK2A1 901/4885MEN1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.